Morgan Stanley Cuts Edwards Lifesciences Corporation (EW) Price Target to $120.00


Adams Diversified Equity Fund Inc. continued to hold its stake in Edwards Lifesciences Corp.

Cohen Lawrence B decreased Edwards Lifesciences Corp (EW) stake by 13.99% reported in 2017Q2 SEC filing. The Partner Investment Management Lp holds 13,938 shares with $1.65 million value, up from 11,015 last quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Amalgamated Bank now controls 25,224 shares worth $2,757,000. TNB Financial acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth about $204,000. In the last ninety days, insiders sold 138,580 shares of company stock worth $15,039,844. Jennison Associates LLC grew its holdings in Edwards Lifesciences Corporation by 6.2% during the third quarter. Checchi Capital Advisers LLC increased its stake in Edwards Lifesciences 3.9% in the second quarter. The stock declined 0.36% or $0.37 reaching $103.48 per share. Finally, Norinchukin Bank The increased its stake in Edwards Lifesciences 0.8% in the second quarter. Scout Investments Inc. now owns 229,855 shares of the medical research company's stock worth $25,125,000 after acquiring an additional 2,127 shares during the period. Institutional investors and hedge funds own 82.69% of the company's stock. The stock rose 0.21% or $0.11 reaching $52.18 per share. The stock has a market cap of $22,200.00, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 1.86 and a beta of 0.46. The stock's 52-week range is $81.12 to $121.45, and its 3-month range is $100.20 to $115.94. Edwards Lifesciences Corp had 84 analyst reports since July 30, 2015 according to SRatingsIntel.

Edwards Lifesciences Corporation (EW) opened at $102.72 on Friday. As of the latest earnings report the EPS was $3.44 with 211.62M shares presently outstanding. The firm had revenue of $821.50 million for the quarter, compared to analyst estimates of $833.85 million. During the same quarter a year ago, the business posted $0.54 earnings per share. The company's revenue was up 11.1% compared to the same quarter a year ago. During the same period in the prior year, the firm earned $0.68 EPS. equities research analysts expect that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year. Maintains Position in Edwards Lifesciences Corp. If you are viewing this article on another website, it was stolen and reposted in violation of United States and worldwide copyright & trademark law.

More notable recent Edwards Lifesciences Corp (NYSE:EW) news were published by: which released: "Edwards Lifesciences (EW) CEO Mike Mussallem on Q3 2017 Results - Earnings ..." on October 25, 2017, also with their article: "Cramer's lightning round: I'm a buyer of Edwards Lifesciences despite the ..." published on October 31, 2017, published: "Edwards SAPIEN 3 Transcatheter Valve Demonstrates Significant Cost Savings ..." on October 31, 2017.

Several brokerages have issued reports on EW.

The average Wall Street analyst rating for Edwards Lifesciences Corporation is Strong Buy, according to the average of 15 analyst scores. Canaccord Genuity reaffirmed a "buy" rating and issued a $155.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Sunday, October 8th. Finally, Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a "hold" rating to a "buy" rating and set a $130.00 price objective for the company in a research report on Tuesday, July 18th. RBC Capital Markets maintained it with "Buy" rating and $130.0 target in Monday, October 2 report.

Morgan Stanley lowered the price target on October 26 cutting the projection from $133.00 to $120.00 with a rating of "Overweight". Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. On Tuesday, May 30 the stock rating was maintained by RBC Capital Markets with "Buy". The stock saw a fall in short interest of -4.22% between October 13, 2017 and October 31, 2017. The stock was sold at an average price of $120.04, for a total value of $1,638,546.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The firm has "Outperform" rating by William Blair given on Monday, August 28. The shares were sold at an average price of $111.81, for a total transaction of $2,119,917.60. The disclosure for this sale can be found here. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. The Firm offers a range of services to its customers, including design and development, engineering services, supply chain management, new product introduction, component sourcing, electronics manufacturing, assembly and test, complex mechanical assembly, systems integration, precision machining, order fulfillment, logistics and after-market fix and return services.



Related Posts

Traders Buy Eli Lilly and Company (LLY) on Weakness After Insider Selling
More notable recent Eli Lilly and Co (NYSE:LLY) news were published by: which released: "Eli Lilly & Co". As it upholds an amended rate with more EPSGR it is prone to be a good target. (NYSE:JWN) rating on Friday, August 12.

Lam Research Corporation (LRCX) Holdings Cut by BTC Capital Management Inc
Sprott Inc increased Federated Invs Inc Pa Cl B (NYSE:FII) stake by 25,000 shares to 230,000 valued at $6.50 million in 2017Q2. BDO Wealth Advisors LLC bought a new position in Lam Research Corporation in the second quarter valued at about $118,000.

EPS Forecast Revision Trends: Eastman Chemical Company (EMN)
The basic materials company reported $2.19 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.16. In the most updated research from a number of analysts on Wall Street, the company gets 8 Buys and 2 Sell among 14 analysts.

NYC MTA cuts 'ladies and gentlemen' announcements for gender-neutral phrasing
Bus drivers and subway conductors are reportedly told to use words such as "passengers", "riders" and "everyone". A bulletin was sent to transit staff this week notifying them of the change, which went into effect immediately.

Gareon Conley's Rookie Season Is Over, Raiders Place CB on Reserve/Injured List
We'll see what's happening over the weekend and early (next) week and see what he can do. "He came in hitting the ground running". He was feeling better, then he had a setback. if he can't go, then he can't go and we're going to have to move on.

British doctor saves himslef by punching shark during surfing attack in Australia
But lifeguards spotted a great white shark and a bronze whaler in the area shortly after the horrific incident. A man was injured after being hit by a shark while surfing at a beach on the NSW Central Coast.

Earnings on the Doorstep For The TJX Companies, Inc
Kbc Group Nv decreased Cadence Design System Inc (NASDAQ:CDNS) stake by 15,338 shares to 28,404 valued at $951,000 in 2017Q2. Shares for $303,211 were sold by Canestrari Kenneth on Thursday, June 1. 31 funds opened positions while 54 raised stakes.

Traders Actions to Focus: Denbury Resources Inc. (DNR), Groupon, Inc. (GRPN)
Denbury Resources Inc . shares increased 34.85 percent over the past week and rose 41.27 percent over the previous month. Tang Capital Management Llc holds 17.5% of its portfolio in Ignyta Inc for 4.76 million shares. (NYSE:DNR) is 0.003350.

Warring Indiana alcohol lobbyists reach deal on Sunday sales
Now, under a new agreement, both sides said they're in favor of Sunday sales. Right now, only liquor stores can sell the product.

Pictet Asset Management Ltd. Cuts Stake in Pepsico, Inc. (PEP)
It is negative, as 44 investors sold PEP shares while 778 reduced holdings. 117 funds opened positions while 502 raised stakes. The Wisconsin-based Convergence Inv Prtnrs Limited Liability Corporation has invested 0.05% in PepsiCo, Inc. (NYSE:PEP).

© 2015 ExpressNewsline. All Rights reserved.